Literature DB >> 16648001

Hypohidrosis during topiramate treatment: a rare and reversible side effect.

Caterina Cerminara1, Stefano Seri, Roberta Bombardieri, Mariangela Pinci, Paolo Curatolo.   

Abstract

Topiramate is an antiepileptic drug with a beneficial clinical effect on various seizure types. Topiramate does not seem to be associated with serious adverse effects and is also well tolerated in pediatric patients. Only few cases of hypohidrosis have been described. This report presents one young patient with complex partial seizures who was medicated with topiramate when she developed fatigue, headache, intermittent hyperthermia, inability to produce sweat secretion, and dryness of the skin. Reduced sweat response was determined using the Wescor Macroduct collection procedure. Topiramate was discontinued, and within 3 weeks a repeat sweat test was completely normal. At that time, clinical signs had also disappeared. Hypohidrosis is an uncommon and reversible side effect reported in association with topiramate therapy. It is rare in patients on monotherapy. Although a definite causal relationship still needs to be established, this side effect might be attributed to an autonomic dysfunction by inhibition of isoenzymes of carbonic anhydrase localized in human eccrine sweat glands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648001     DOI: 10.1016/j.pediatrneurol.2005.10.004

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  12 in total

1.  Oligohydrosis underestimated side effect with topiramate treatment.

Authors:  Eva L W Fung; Edmund A S Nelson
Journal:  Indian J Pediatr       Date:  2007-07       Impact factor: 1.967

2.  Rash Associated With Panic Attacks.

Authors:  Shady S Shebak; James Pinkston; Rizwan Ali
Journal:  Prim Care Companion CNS Disord       Date:  2016-02-11

Review 3.  Currently available antiepileptic drugs.

Authors:  Steven C Schachter
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 4.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 5.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 6.  Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.

Authors:  William P Cheshire; Robert D Fealey
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

8.  Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features.

Authors:  Mikail Nourredine; Lucie Jurek; Bernard Angerville; Yannick Longuet; Julia de Ternay; Alain Derveaux; Benjamin Rolland
Journal:  CNS Drugs       Date:  2021-02-16       Impact factor: 5.749

Review 9.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

10.  Topiramate in the treatment of partial and generalized epilepsy.

Authors:  Edward Faught
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.